These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 29993139)

  • 41. Salivary duct carcinoma: Clinicopathologic features, morphologic spectrum, and somatic mutations.
    Luk PP; Weston JD; Yu B; Selinger CI; Ekmejian R; Eviston TJ; Lum T; Gao K; Boyer M; O'Toole SA; Clark JR; Gupta R
    Head Neck; 2016 Apr; 38 Suppl 1():E1838-47. PubMed ID: 26699379
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Salivary duct carcinoma.
    D'heygere E; Meulemans J; Vander Poorten V
    Curr Opin Otolaryngol Head Neck Surg; 2018 Apr; 26(2):142-151. PubMed ID: 29373327
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases.
    Jaehne M; Roeser K; Jaekel T; Schepers JD; Albert N; Löning T
    Cancer; 2005 Jun; 103(12):2526-33. PubMed ID: 15900577
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High expression level of geminin predicts a poor clinical outcome in salivary gland carcinomas.
    Yamazaki M; Fujii S; Murata Y; Hayashi R; Ochiai A
    Histopathology; 2010 Jun; 56(7):883-92. PubMed ID: 20497246
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Salivary duct carcinoma with rhabdoid features: a salivary counterpart of pleomorphic lobular carcinoma of the breast.
    Kusafuka K; Kawasaki T; Maeda M; Yamanegi K; Baba S; Ito Y; Inagaki H; Nakajima T
    Histopathology; 2017 Jan; 70(2):164-173. PubMed ID: 27079821
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review.
    Uijen MJM; Lassche G; van Engen-van Grunsven ACH; Tada Y; Verhaegh GW; Schalken JA; Driessen CML; van Herpen CML
    Cancer Treat Rev; 2020 Sep; 89():102069. PubMed ID: 32717621
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Subsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, PLAG1 or HMGA2 rearrangements, and common genetic alterations.
    Chiosea SI; Thompson LD; Weinreb I; Bauman JE; Mahaffey AM; Miller C; Ferris RL; Gooding WE
    Cancer; 2016 Oct; 122(20):3136-3144. PubMed ID: 27379604
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinicopathological study of intraductal carcinoma of the salivary gland, with emphasis on the apocrine type.
    Hsieh MS; Lee YH; Jin YT; Kuo YJ
    Virchows Arch; 2020 Oct; 477(4):581-592. PubMed ID: 32383006
    [TBL] [Abstract][Full Text] [Related]  

  • 49. FOXA1 and AR in invasive breast cancer: new findings on their co-expression and impact on prognosis in ER-positive patients.
    Rangel N; Fortunati N; Osella-Abate S; Annaratone L; Isella C; Catalano MG; Rinella L; Metovic J; Boldorini R; Balmativola D; Ferrando P; Marano F; Cassoni P; Sapino A; Castellano I
    BMC Cancer; 2018 Jul; 18(1):703. PubMed ID: 29970021
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of postoperative radiotherapy and HER2/new overexpression in salivary duct carcinoma : A monocentric clinicopathologic analysis.
    Haderlein M; Scherl C; Semrau S; Lettmaier S; Hecht M; Erber R; Iro H; Fietkau R; Agaimy A
    Strahlenther Onkol; 2017 Nov; 193(11):961-970. PubMed ID: 28828496
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reciprocal and Autonomous Glucocorticoid and Androgen Receptor Activation in Salivary Duct Carcinoma.
    Mitani Y; Lin SH; Pytynia KB; Ferrarotto R; El-Naggar AK
    Clin Cancer Res; 2020 Mar; 26(5):1175-1184. PubMed ID: 31772120
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The expression of programed death ligand-1 could be related with unfavorable prognosis in salivary duct carcinoma.
    Sato F; Akiba J; Kawahara A; Naito Y; Ono T; Takase Y; Murata K; Abe H; Yamaguchi T; Miyoshi H; Abe Y; Mihara Y; Tanikawa M; Akashi M; Kurose H; Umeno H; Yano H
    J Oral Pathol Med; 2018 Aug; 47(7):683-690. PubMed ID: 29719073
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinicopathologic study of salivary duct carcinoma and the efficacy of androgen deprivation therapy.
    Yamamoto N; Minami S; Fujii M
    Am J Otolaryngol; 2014; 35(6):731-5. PubMed ID: 25087467
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biomarker immunoprofile in salivary duct carcinomas: clinicopathological and prognostic implications with evaluation of the revised classification.
    Takase S; Kano S; Tada Y; Kawakita D; Shimura T; Hirai H; Tsukahara K; Shimizu A; Imanishi Y; Ozawa H; Okami K; Sato Y; Sato Y; Fushimi C; Okada T; Sato H; Otsuka K; Watanabe Y; Sakai A; Ebisumoto K; Togashi T; Ueki Y; Ota H; Hanazawa T; Chazono H; Osamura RY; Nagao T
    Oncotarget; 2017 Aug; 8(35):59023-59035. PubMed ID: 28938615
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic Implication of Histopathologic Indicators in Salivary Duct Carcinoma: Proposal of a Novel Histologic Risk Stratification Model.
    Nakaguro M; Sato Y; Tada Y; Kawakita D; Hirai H; Urano M; Shimura T; Tsukahara K; Kano S; Ozawa H; Okami K; Sato Y; Fushimi C; Shimizu A; Takase S; Okada T; Sato H; Imanishi Y; Otsuka K; Watanabe Y; Sakai A; Ebisumoto K; Togashi T; Ueki Y; Ota H; Saigusa N; Takahashi H; Ando M; Hanazawa T; Nagao T
    Am J Surg Pathol; 2020 Apr; 44(4):526-535. PubMed ID: 31764219
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic and histogenetic roles of gene alteration and the expression of key potentially actionable targets in salivary duct carcinomas.
    Shimura T; Tada Y; Hirai H; Kawakita D; Kano S; Tsukahara K; Shimizu A; Takase S; Imanishi Y; Ozawa H; Okami K; Sato Y; Sato Y; Fushimi C; Takahashi H; Okada T; Sato H; Otsuka K; Watanabe Y; Sakai A; Ebisumoto K; Togashi T; Ueki Y; Ota H; Ando M; Kohsaka S; Hanazawa T; Chazono H; Kadokura Y; Kobayashi H; Nagao T
    Oncotarget; 2018 Jan; 9(2):1852-1867. PubMed ID: 29416736
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma.
    van Boxtel W; Locati LD; van Engen-van Grunsven ACH; Bergamini C; Jonker MA; Fiets E; Cavalieri S; Tooten S; Bos E; Quattrone P; Verhaegh GW; Schalken JA; Licitra L; van Herpen CML;
    Eur J Cancer; 2019 Mar; 110():62-70. PubMed ID: 30771738
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinicopathological features and treatment outcomes of the rare, salivary duct carcinoma of parotid gland.
    Al-Qahtani KH; Tunio MA; Bayoumi Y; Gurusamy VM; Bahamdain FA; Fatani H
    J Otolaryngol Head Neck Surg; 2016 May; 45(1):32. PubMed ID: 27184361
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Increased expression of CD147 and MMP-9 is correlated with poor prognosis of salivary duct carcinoma.
    Piao S; Zhao S; Guo F; Xue J; Yao G; Wei Z; Huang Q; Sun Y; Zhang B
    J Cancer Res Clin Oncol; 2012 Apr; 138(4):627-35. PubMed ID: 22215147
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Association between high expression of phosphorylated Akt and mammalian target of rapamycin and improved survival in salivary gland adenoid cystic carcinoma.
    Ouyang DQ; Liang LZ; Ke ZF; Zheng GS; Weng DS; Yang WF; Su YX; Liao GQ
    Head Neck; 2017 Jun; 39(6):1145-1154. PubMed ID: 28230926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.